Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | FNTA | P49354 | 1/20 | 0.58 |
| ▸ | FNTB | P49356 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482567 | 0.89 | POLB (0.74) | POLBKDM4EALDH1A1CA12CA1 | |
| SCHEMBL29888792 | 0.89 | POLB (0.74) | POLBKDM4EALDH1A1CA12CA1 | |
| SCHEMBL9460748 | 0.87 | POLB (0.71) | POLBKDM4EALDH1A1CA12CA1 | |
| SCHEMBL23665073 | 0.87 | POLB (0.55) | POLBKDM4EALDH1A1CA12CA1 | |
| Bicarbonate SCHEMBL11202875 | 0.85 | KDM4E (0.46) | POLBKDM4EALDH1A1CA12CA1 | |
| SCHEMBL6629741 | 0.82 | SIRT1 (0.65) | POLBKDM4EALDH1A1CA12CA1 | |
| Tetramethylammonium Ion SCHEMBL9460521 | 0.82 | POLB (0.63) | POLBKDM4EALDH1A1CA12CA1 | |
| Tetramethylammonium Ion SCHEMBL9460352 | 0.82 | POLB (0.63) | POLBKDM4EALDH1A1CA12CA1 | |
| SCHEMBL10987023 | 0.81 | HSP90AA1 (0.44) | POLBKDM4EALDH1A1CA12CA1 | |
| Guanidine SCHEMBL9133806 | 0.80 | POLB (0.61) | POLBKDM4EALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158623-B2 | Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-04-17 | — | — | US | disclosed |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE | 2010-07-08 | — | — | US | disclosed |
| EP-2199295-A1 | COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2010-06-23 | — | — | EP | disclosed |
| CN-101687886-A | Seven-membered ring compound and pharmaceutical application thereof in preventing and treating diabetes and metabolic syndrome | SHANGHAI INST MATERIA MEDICA | 2010-03-31 | — | — | CN | disclosed |
| CN-1441637-A | Compositions for repelling crawling insects | BAYER AG (DE) | 2003-09-10 | — | — | CN | disclosed |
| EP-1086079-B1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA A S (CZ) | 2003-05-07 | — | — | EP | disclosed |
| US-6303612-B1 | USED AS ANTIINFLAMMATORY AND/OR ANTIASTHMATIC AGENTS | LECIVA, A.S. (CZ) | 2001-10-16 | — | — | US | disclosed |
| EP-1086079-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | Leciva, A.S. (CZ) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999067208-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA, A.S. (CZ) | 1999-12-29 | — | — | WO | disclosed |
| EP-0137395-B1 | 4-(HYDROXYPHENYLTHIO)-BENZOATES | CIBA-GEIGY AG (CH) | 1987-11-04 | — | — | EP | disclosed |
| EP-0137395-A2 | 4-(Hydroxyphenylthio)-benzoates | CIBA-GEIGY AG (CH) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | GPR119, CYP11B1, HSD11B1 | POLB 4766/4885KDM4E 4346/4885ALDH1A1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.